Yu, X., Zhang, X., Zhang, Z., Lin, Y., Wen, Y., Chen, Y., . . . Zhang, L. (2018). First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: A single institution’s clinical practice experience. Cancer Commun (Lond).

Yu, Xiangyang, Xuewen Zhang, Zichen Zhang, Yongbin Lin, Yingsheng Wen, Yongqiang Chen, Weidong Wang, a Lanjun Zhang. "First-generation EGFR Tyrosine Kinase Inhibitor Therapy in 106 Patients With Compound EGFR-mutated Lung Cancer: A Single Institution’s Clinical Practice Experience." Cancer Commun (Lond) 2018.

Yu, Xiangyang, et al. "First-generation EGFR Tyrosine Kinase Inhibitor Therapy in 106 Patients With Compound EGFR-mutated Lung Cancer: A Single Institution’s Clinical Practice Experience." Cancer Commun (Lond) 2018.